Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease
Published
Nov 4, 2020 8:15am EST
Alzheimer’s Patients Treated with Sumifilam Showed a Statistically Significant (p
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.